Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next ...
Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer ...
Business Wire8 天
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next ...
Ellipses has agreed to in-license global rights ... In October 2024, key research findings were published in the prestigious journal Science Immunology, demonstrating the potential of EP0089 ...